Article Per Year (5 Year)
p-Index From 2020 - 2025
0.751
P-Index
This Author published in this journals
All Journal Pharmasipha Jurnal Ners The Health Researchers Journal
Riska Yuli Nurvianthi
Stikes Bhakti Pertiwi Luwu Raya
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Nursing Public Health

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
Analisis penggunaan obat resep dokter pasien Generalized Anxiety Disorder (GAD) di RSUD Andi Djemma Masamba Yuli Nurvianthi, Riska; Djafar, Tanwir; Jehanam, Tonsisius; Delta, Delta; Safitri, Alma
Pharmasipha : Pharmaceutical Journal of Islamic Pharmacy Vol. 8 No. 2 (2024): September
Publisher : University Of Darussalam Gontor

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21111/pharmasipha.v8i2.11860

Abstract

Gangguan Cemas Menyeluruh adalah salah satu jenis gangguan mental dengan prevalensi sebanyak 12,8% di Sulawesi Selatan. Pemberian obat anticemas harus secara cermat (pemilihan jenis obat dan pengaturan regimen dosis). Penelitian ini bertujuan untuk menganalisa dan menggambarkan pola penggunaan obat anticemas pada kasus gangguan cemas menyeluruh dikaitkan dengan data klinik pasien di Poli Jiwa RSUD Andi Djemma Masamba Metode yang digunakan dalam penelitian ini adalah secara observasional retrospektif pada periode 4 April hingga 27 Juni 2023 di Poli Jiwa Rumah Sakit Umum Daerah Andi Djemma Masamba. Hasil penelitian menunjukkan dari 40 pasien mayoritas terdiri dari perempuan (70%) dengan rentang usia terbanyak yaitu 35 - 44 tahun (35%). Pasien paling banyak bertempat tinggal di Masamba (15%). Terapi yang diterima pasien GAD adalah obat anticemas golongan benzodiazepin meliputi alprazolam (43%), lorazepam (26%), klobazam (21%), dan diazepam (10%). Kesimpulannya, pemilihan obat dan pemberian dosis telah sesuai dengan pustaka dan dari segi kesesuaian dosis, tidak ditemukan problema obat yang berpotensi terjadi adalah efek samping seperti rasa mengantuk, depresi, sakit kepala, ataksia, insomnia, halusinasi dan mual. Sehingga diharapkan selanjutnya melibatkan sampel yang lebih besar serta menggunakan metode penelitian yang lebih spesifik.   Kata kunci: :  anticemas, cemas, obat, problema obat
COMMUNITY EDUCATION IN REDUCING THE RISK OF DIMENHYDRINATE MISUSE AS A SEDATIVE-HYPNOTIC IN LAMASI VILLAGE IN 2024 Nurvianthi, Riska Yuli; Asmal, Adhitama; Djafar, Tanwir; Parinding, Indah Purnamasari; Wahyuddin
The Health Researcher's Journal Vol. 2 No. 3 (2025): The Health Researchers Journal
Publisher : The SDGS Forum Communication

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.00000/dvgh4p66

Abstract

The misuse of dimenhydrinate as a sedative-hypnotic can pose serious health risks. Dimenhydrinate, which is commonly used to prevent nausea and dizziness due to motion sickness, is often misused as a sleep aid. This study aims to educate the community of Lamasi Village about the risks of dimenhydrinate misuse and to enhance their understanding of the safe use of this drug. Using a quasi-experimental method with quantitative analysis, this study involved 30 respondents selected through purposive sampling. Data was collected using pre-test and post-test questionnaires via a door-to-door method. The results show a significant improvement in the community's understanding and compliance after the educational intervention. The average pre-test attitude score increased from 8.10 to 9.83, and the compliance score increased from 17.07 to 23.90. The education provided proved effective in reducing the misuse of dimenhydrinate and improving the community’s understanding of its risks.
INNOVATION AND CHALLENGES IN THE DEVELOPMENT OF BIOSIMILARS: GLOBAL REGULATIONS AND THEIR APPLICATION IN CANCER THERAPY (2025) Nurvianthi, Riska Yuli; Gisman, Rahmiaty
The Health Researcher's Journal Vol. 2 No. 3 (2025): The Health Researchers Journal
Publisher : The SDGS Forum Communication

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.00000/q0rcsm38

Abstract

Biosimilars offer a more affordable alternative to reference biologic drugs, providing a solution to reduce treatment costs, particularly in cancer therapy. However, their development faces challenges, especially regarding regulatory differences between countries, which delay their global distribution. This article reviews the latest developments in biosimilar development, particularly in cancer treatment. The primary focus is on the regulatory challenges encountered in the development and distribution of biosimilars, as well as their application in cancer therapy, with emphasis on the acceptance challenges faced by healthcare professionals and patients. This literature review examines recent studies on biosimilars, including regulatory approval processes, clinical applications, and the economic impact on cancer treatment. The analysis also compares regulations across countries and highlights the success of biosimilars in replacing reference biologic drugs such as trastuzumab and rituximab. While innovations in advanced statistical methods have been implemented to expedite the approval process, inconsistent regulations across countries remain a significant barrier. Biosimilars have proven effective in replacing more expensive biologic drugs, but challenges in acceptance by the medical community and patients persist. Some countries have begun accepting biosimilars as alternatives, though regulatory gaps and uncertainties about long-term efficacy continue to pose obstacles. The development of biosimilars has the potential to reduce cancer treatment costs, but regulatory challenges and acceptance by healthcare professionals and patients must be addressed. Further research is needed to explore long-term effectiveness and harmonize global regulations to accelerate biosimilar adoption in cancer therapy.
Innovation of Blockchain For Controlling Prescription Drug Abuse; a Case Study of Puskesmas in Palopo City Nurvianthi, Riska Yuli; Warsid, Aisyah
Jurnal Ners Vol. 9 No. 4 (2025): OKTOBER 2025
Publisher : Universitas Pahlawan Tuanku Tambusai

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31004/jn.v9i4.49684

Abstract

Prescription drug management and oversight are critical to ensuring the effectiveness of pharmacy management in healthcare settings. In community health centers, challenges such as lack of transparency in drug distribution, reliance on error-prone manual record-keeping, and poor integration with digital systems hinder effective pharmaceutical management. This study explores the application of blockchain technology in pharmaceutical management, focusing on enhancing transparency, improving drug distribution efficiency, and ensuring compliance with pharmaceutical regulations. A mixed-methods approach combining survey analysis and participant observation was employed. Data were collected from health workers and patients through surveys conducted before and after blockchain implementation. Additionally, in-depth interviews with pharmacists and health workers were conducted, and direct observations of drug distribution processes and electronic record-keeping were performed. Blockchain implementation led to a significant 85% improvement in drug monitoring effectiveness, an 82% increase in drug distribution transparency, and a 40% reduction in prescription errors. The technology also enabled the detection of counterfeit prescriptions and optimized the pharmaceutical supply chain. Blockchain technology significantly improves pharmaceutical management by enhancing supply chain efficiency, increasing transparency in drug distribution, and ensuring compliance with pharmaceutical regulations. Further research is needed to evaluate its cost-effectiveness and assess health systems' readiness for wider integration of blockchain technology.
Co-Authors Aisyah Warsid Asmal, Adhitama Delta, Delta Djafar, Tanwir Gisman, Rahmiaty Jehanam, Tonsisius Parinding, Indah Purnamasari Safitri, Alma Wahyuddin